Trulieve Earns Its Spot on the S&P Indices

TALLAHASSEE – Trulieve Cannabis Corp. announced that S&P Dow Jones Indices had added the company to the S&P Total Market Index, the S&P Completion Index, and their respective health care sub-indices – S&P TMI Health Care and S&P CI Health Care. Shares climbed 3.1% to $11.86 in New York on Tuesday, and trading volume by early afternoon had already matched the entirety of the prior session.

“Index inclusion raises visibility for Trulieve, ultimately improving liquidity and attracting new institutional investors,” CEO Kim Rivers said in a press release, framing it as a continuation of the company’s recent structural advances.

S&P’s index methodology restricts membership to U.S.-domiciled companies trading on eligible American exchanges – rules that have historically barred plant-touching Cannabis operators from qualifying at all. Trulieve cleared that standard through two discrete actions taken over roughly a hundred days.

In June, the company became the first U.S. Cannabis company to begin trading on the New York Stock Exchange (NYSE) – a door that opened after federal rescheduling of medical Cannabis to Schedule III in April, allowing DEA-registered operators to qualify for major domestic exchange listings. Then on August 11, Trulieve completed its redomicile from British Columbia to Delaware, formally becoming a U.S.-incorporated entity and satisfying the second eligibility requirement.

S&P reconstitutes the Total Market Index after the close of the third Friday of September, which fell on September 18. Volume in Trulieve on that day reached 12.7 million shares [roughly eight times the sessions on either side of it, and the heaviest since the June listing] – a signal that institutional repositioning had already started before the announcement.

The Practical Weight of Index Membership

Passive funds that track the entire U.S. stock market can now own a cannabis company. The S&P Total Market Index is one of the broadest equity benchmarks published by S&P Dow Jones Indices, spanning U.S.-domiciled companies across the full market-cap range. The Completion Index draws from the same universe, minus the S&P 500 – effectively the mid-, small-, and micro-cap tier.

Vanguard’s Extended Market Index Fund, which tracks the Completion Index and buys its members outright where it can, held $95.4 billion on August 31. Passive funds of that scale do not select stocks. They hold what the index dictates. Trulieve is now on that list.

Where Peers Stand

Curaleaf Holdings trades in Toronto. Green Thumb Industries remains on the Canadian Securities Exchange. Neither qualifies under S&P’s eligibility rules, which exclude companies trading only on Canadian exchanges or U.S. over-the-counter markets. Glass House Brands [the second U.S. Cannabis company to reach the NYSE] was not captured in this reconstitution cycle. The next review runs in December.

Trulieve starts this new phase from a position of financial stability. Second-quarter revenue came in at $271 million at a 60% gross margin, with adjusted EBITDA of $98 million and $325 million in cash at the end of June. The company runs 207 dispensaries and 3.5 million sq. feet of cultivation and processing space across Florida, Georgia, Pennsylvania, and West Virginia.

Wrapping up, index inclusion does not put cash on Trulieve’s balance sheet or add a location to its retail footprint. What it does is expand the pool of capital that is structurally permitted [in some cases required] to own the stock. For a sector that has spent the better part of a decade pursuing institutional credibility, that distinction is real. The rescheduling-to-NYSE-to-Delaware-to-index chain Trulieve has now completed represents a replicable model. Operators still trading on Canadian exchanges are watching the December reconstitution date with more than casual interest.